BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) is set to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, where presentations will be available from November 23 to December 3, 2020. An archived replay will be accessible for 90 days on BeiGene’s investor webpages.
As a leading biotechnology firm, BeiGene is focused on innovative medicines, specifically in oncology, with products like BRUKINSA® and tislelizumab. The company's global team is dedicated to enhancing treatment options for patients worldwide.
- None.
- None.
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020.
An archived replay will be available for 90 days following the event in the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com.
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
